BioSpecifics Technologies Corp. Announces Presentation of Additional Phase III Data from XIAFLEX® Clinical Trials for Peyronie's Disease at SMSNA/ISSM Joint Annual Meeting

BioSpecifics Technologies Corp. BSTC, a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX® in Europe and Eurasia, today announced that additional data will be presented from the Phase III clinical program of XIAFLEX for the treatment of Peyronie's disease conducted by BioSpecifics' partner Auxilium Pharmaceuticals, Inc. (Auxilium) and known as IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies). These data will be presented at two oral presentations at the Sexual Medicines Society of North America (SMSNA)/International Society for Sexual Medicine (ISSM) Joint Annual Meeting on August 27 and 29, 2012 in Chicago, IL. "These data highlight the psychological severity of this condition, which currently has no FDA-approved pharmaceutical therapy, and complement the positive top-line Phase III results from the two IMPRESS clinical trials that we reported in June," commented Thomas L. Wegman, President of BioSpecifics. "We are excited about the potential for XIAFLEX as the first and only biologic therapy for the treatment of Peyronie's disease and we look forward See full press release